
Forget tariffs — this U.S. shoe company vows not to hike its prices
Although the midsize company, based in Portland, Oregon, operates in an industry that is highly exposed to tariffs, Keen tells customers that it will keep prices steady this year no matter how tariffs affect its costs. That's no idle pledge calculated to preserve market share — Keen has been steadily retooling the business for years to protect itself from sudden shifts in global trade and the vagaries of geopolitics.
"We have been preparing for this for over a decade. Early on, we saw the risks of being overdependent on any one country, so we made the decision to diversify our supply chain well beyond China," Chief Operating Officer Hari Perumal told CBS MoneyWatch.
The 22-year-old company, with 650 U.S. employees and owned by design and brand management company Fuerst Group, has worked to reduce its dependance on Chinese manufacturing while expanding its U.S. presence and diversifying its supply chains.
President Trump's tariffs are upending retailer supply chains, forcing them to devise workarounds. That can mean moving manufacturing to another foreign country with lower tariffs or investing in U.S.-based production. For small businesses, tariff-driven uncertainty can mean shutting operations down altogether when the financials no longer add up.
Shoe and clothing prices could soar
Footwear companies are particularly vulnerable to the upheaval caused by President Trump's trade war given their reliance on China, where 36%, or $9.8 billion's worth, of imported footwear sold in the U.S. is made, according to a TD Cowen analysis of international trade data.
For that reason, tariffs are expected to hit footwear and apparel companies hard, and that impact will be felt by American consumers as well, according to Jason Judd, a global supply-chain expert and executive director of Cornell University's Global Labor Institute.
In 2023, U.S. households spent an average of about $1,700 per year on footwear and apparel, Judd said. He expects that figure to surge 70% in the short term, to $2,800 per family, because of tariff-related price hikes. In the coming years, meanwhile, consumers are still likely to be paying more for footwear and clothing because of higher global tariffs.
"That pain will lessen as terms and sourcing patterns change, but the longer-term costs per family will still be around a $425 increase per year."
The abrupt change in tariff policies is already rippling across the industry. German sportswear giant Adidas last month warned U.S. customers that "cost increases due to higher tariffs will eventually cause price increases." And retailers across various industries, from apparel to food, have started passing some of the cost from higher import taxes to consumers in the form of "tariff surcharges."
"We saw the writing on the wall"
Today, Keen operates plants in Shepherdsville, Kentucky; the Dominican Republic; and Thailand, where it handles a third of the company's global production. It also contracts with manufacturing partners in Cambodia, India and Vietnam, all of which are subject to impending new U.S. levies. Cambodia faces a country-specific tariff rate of 49%, while Vietnam and India face levies of 47% and 27%, respectively.
"We do have 10% exposure in those countries, but the 10% tariff we're dealing with is significantly lower than what other companies are facing on products that would come out of China," Perumal told CBS MoneyWatch.
Back in 2015, executives at Keen were already taking note of rising labor costs in China. Today, the company's broad supply chain helps it spread costs across the company, its manufacturing partners and their suppliers, he said.
"We are making a conscious decision not to increase prices, but that's shared by our partners," he said. "They share some of the costs with us, then they go to the company they buy materials from, and those tier-one suppliers share some of the costs as well."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi
We recently published . Hudbay Minerals Inc. (NYSE:HBM) is one of the best-performing stocks on Wednesday. Hudbay Minerals grew its share prices for a second day on Wednesday, up 15.03 percent to close at $11.33 apiece, following an impressive earnings performance and a $600-million investment from Mitsubishi Corp. In its updated report, Hudbay Minerals Inc. (NYSE:HBM) said it swung to a net income attributable to shareholders of $117.7 million from an attributable net loss of $16.5 million in the same period last year, driven by higher gross margins and strong cost control. Revenues increased by 26 percent to $536.4 million from $425.5 million year-on-year. 'With the strong performance in the first half of the year, we are reaffirming our full year consolidated production guidance and are favourably tracking well below our full year consolidated cost guidance for 2025,' said Hudbay Minerals Inc. (NYSE:HBM) President and CEO Peter Kukielski. For the full-year period, the company is targeting to produce between 117,000 and 149,000 tons of copper, as well as 247,500 to 308,000 ounces of gold. In other news, Hudbay Minerals Inc. (NYSE:HBM) was able to raise $600 million in fresh funds from Mitsubishi Corp. after the latter acquired a 30-percent stake in Copper World LLC. Under the agreement, Mitsubishi will pay an upfront cash of $420 million, with the balance to serve as a matching contribution within an 18-month period. While we acknowledge the potential of HBM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?
We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Wednesday. Paramount Skydance extended its rally to touch a new high on Wednesday, finishing up by 36.74 percent at $15 apiece, with a former hedge fund manager calling it a 'meme' stock. In a social media post, Mad Money host and former hedge fund manager Jim Cramer said Paramount Skydance Corp. (NASDAQ:PSKY) is a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments. Paramount Skydance Corp. (NASDAQ:PSKY) climbed by as high as 60 percent at intra-day trading to hit $17.53 before paring gains to finish slightly lower during the session. In recent news, the company bagged a new $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. cellanr, CC BY-SA 2.0 , via Wikimedia Commons As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data